quinta-feira, 4 de dezembro de 2014


http://bmjopen.bmj.com/content/4/11/e006140.full?g=w_aim_open_tab


Bee venom acupuncture for rheumatoid arthritis: a systematic review of randomised clinical trials

  1. Myeong Soo Lee1
+Author Affiliations
  1. 1Medical Research DivisionKorea Institute of Oriental MedicineDaejeon, South Korea
  2. 2Medical Culture & Informatics Research DivisionKorea Institute of Oriental MedicineDaejeon, South Korea
  3. 3Division of Acupuncture & Moxibustion MedicineKyung Hee Korean Medicine Hospital, Kyung Hee UniversitySeoul, South Korea
  1. Correspondence toDr Myeong Soo Lee; drmslee@gmail.com
  • Received 18 July 2014
  • Revised 14 October 2014
  • Accepted 15 October 2014
  • Published 7 November 2014


Abstract

Objective To assess the clinical evidence for bee venom acupuncture (BVA) for rheumatoid arthritis (RA).
Design Systematic review of randomised controlled trials (RCTs).
Setting We searched 14 databases up to March 2014 without a language restriction.
Participants Patients with RA.
Intervention BVA involved injecting purified, diluted BV into acupoints. We included trials on BVA used alone or in combination with a conventional therapy versus the conventional therapy alone.
Primary outcomes Morning stiffness, pain and joint swelling
Secondary outcomes Erythrocyte sedimentation rate (ESR), C reactive protein (CRP), rheumatoid factor, the number of joints affected by RA and adverse effects likely related to RA.
Results A total of 304 potentially relevant studies were identified; only one RCT met our inclusion criteria. Compared with placebo, BVA may more effectively improve joint pain, swollen joint counts, tender joint counts, ESR and CRP but was not shown to improve morning stiffness.
Conclusions There is low-quality evidence, based on one trial, that BVA can significantly reduce pain, morning stiffness, tender joint counts, swollen joint counts and improve the quality of life of patients with RA compared with placebo (normal saline injection) control. However, the number of trials, their quality and the total sample size were too low to draw firm conclusions.
Trial registration number PROSPERO 2013: CRD42013005853.